Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, provides an overview of recent advances in CAR-T therapy for follicular lymphoma (FL). Axicabtagene ciloleucel (axi-cel) was the first CAR-T therapy to be approved in FL. The promising results of the ZUMA-5 (NCT03105336) and ELARA (NCT03568461) studies are expected to lead to the approval of tisagenlecleucel (tisa-cel) in relapsed/refractory (R/R) FL. Further longitudinal data is required to better understand the impact of CAR-T therapy in patients with FL, as well as to determine which patients are most likely to benefit from this immunotherapy. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Dholaria Bhagirathbhai, MBBS, Vanderbilt University Medical Center, Nashville, TN, shares his thoughts on the most exciting data in CAR-T therapy that will be released at this year’s Tandem Meetings, including results from the CARTITUDE-2 (NCT04133636), ELARA (NCT03568461), and ZUMA-5 (NCT03105336) studies. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Amitkumar Mehta, MD, UAB School of Medicine, Birmingham, AL, comments on his highlights in the field of lymphoma presented at ASH 2021, including the Phase III POLARIX trial (NCT03274492) of polatuzumab vedotin (R-CHP) in diffuse large B-cell lymphoma (DLBCL). Dr Mehta additionally talks on the ZUMA-7 (NCT03391466), TRANSFORM (NCT03575351), BELINDA (NCT03570892), and ELARA (NCT03568461) trials, which all assessed chimeric antigen receptor (CAR) T-cell therapies, as well as bispecific antibodies such as glofitamab and mosunetuzumab. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Nathan Fowler, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an update on the Phase II ELARA trial (NCT03568461), which assessed tisagenlecleucel (tisa-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with follicular lymphoma (FL). Tisa-cel improved progression-free survival across different subtypes of FL, including patients who progressed within 2 years (POD24). Patients who received tisa-cel in an outpatient setting also were less likely to require hospitalization, highlighting the ability for CAR T-cell therapies to be administered in an outpatient setting for patients with a low-risk disease. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.